ARTIVION, INC. (AORT) research
ARTIVION, INC.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $22.61
- As of
Kresmion compiles this page from AORT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ARTIVION, INC. (AORT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-07.
As of . Source: SEC EDGAR filings for AORT. Method and limitations.
Share the AORT intelligence card
See the full AORT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AORT on one page. Preview it with sample data, then open it live with a free account.
Preview the AORT dossierActive signals for AORT
- lowEARNINGS_MISS
Q2-2026: EPS $-0.28 vs $0.0102 estimate, -0.29 on a near-zero consensus
- highCONSENSUS_BUY
3 tracked funds increased AORT this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3222% to AORT (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in AORT
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +6615% to AORT (2026Q2)
FREE, NO ACCOUNT
Every signal on AORT, as it fires
You are seeing 5 of 6 signals recorded on AORT since 2026-07-24.
The five above landed across 2 days. The other 1 were recorded on 1 other days. 4 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AORT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 228903100 · 2026Q2 | $18.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 228903100 · 2026Q2 | $9.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 228903100 · 2026Q2 | $8.7M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 228903100 · 2026Q2 | $1.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AORT
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AORT against its peers
AORT's operating margin of 7.6% ranks in the 83rd percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | AORT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 441M USD | 218M USD | 69 | 20 |
| Gross margin | 64.4% | 64.6% | 50 | 18 |
| Operating margin | 7.6% | -17.5% | 83 | 20 |
| Net margin | 2.2% | -19.1% | 74 | 20 |
| Return on equity | 2.2% | -18.8% | 74 | 20 |
| P / E | 107.7x | n/a | n/a | 4 |
Peers (20): ENOV, BBNX, AVNS, IART, CBLL, SIBN, INMD, QDEL, ESTA, KIDS, SSII, DCTH, MASS, SENS, UFPT, BFLY, TCMD, AXGN, NPCE, NEOG. Left out: LMRI (no annual filing), NHNKF (no annual filing), OSSUY (no annual filing), BWAY (period gap), ALMR (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AORT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AORT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AORT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.